{"id":{"repo_id":"edinburgh","oai_identifier":"oai:era.ed.ac.uk:1842/37167"},"canonical_url":"https://search.ndltd.org/etd/edinburgh/oai:era.ed.ac.uk:1842/37167","repository":{"repo_id":"edinburgh","name":"University of Edinburgh","base_url":"https://era.ed.ac.uk/server/oai/request"},"display":{"title":"Evolutionary origin, cyclic peptide targeting and physiological activation of Peptidyl Arginine Deiminase 4","abstract":"Five peptidylarginine deiminases (PADIs), regulating diverse aspects of human physiology, catalyse the post-translational modification citrullination in mammals. Deregulation of citrullination underlies the development of diverse pathologies and PADI4 is of particular medical interest in autoimmune diseases and in cancer. PADI activation is understood biochemically at the level of the crystal structure where allosteric calcium ion binding drives an extensive conformational change and the nucleophilic cysteine relocates approximately 5-10 Å. The critical open question for the field is how this activation can occur in cells. The calcium concentrations required to drive the conformational change in vitro are supraphysiological by two orders of magnitude and little is understood mechanistically about how cellular signalling events enable PADI enzyme activation. As such, the biological activation and therefore the deregulation of PADIs in diseases have remained enigmatic. This PhD set out to understand the physiological activation and regulation of the PADI4 enzyme. First, I identified a surprising origin of the mammalian PADI enzyme family as deriving from an ancient horizontal gene transfer event from cyanobacteria. A variety of maximum likelihood and Bayesian phylogenetic methods as well as non-parametric protein sequence analyses revealed that animal PADIs did not derive from the last universal common ancestor by conventional vertical descent and instead represent an ancient horizontal acquisition. The cyanobacterial PADI is shown to be active with a more stringent calcium dependency than the mammalian counterpart. This has particular interest as to how mechanisms for physiological activation of the human enzyme may have evolved and provides a rare example of HGT into the human lineage. Then, tractable conditions were established for comparing resting PADI4 to activated PADI4 across a variety of cell systems relevant to innate immunity and pluripotency. Emphasis was placed on identifying cellular stimuli that may be independent of calcium flux or transcriptional changes and in which the levels of PADI4 protein may be stringently controlled and independent from the activating stimulus. In this model system, PADI4 was shown to be activated by canonical Wnt signalling – downstream of recombinant Wnt3a, short-term GSK3β inhibition and chemical Wnt agonism. PADI4 inhibition reduced Wnt-driven transcription in a reporter assay. A role for PADI4 in Wnt signalling would be important for roles in haematopoetic stem cells, in neutrophils, in the establishment of pluripotency and its overexpression in cancer. Future work will be required to confirm these exciting effects in a physiologically relevant context. Next, work was undertaken to screen a vast library of peptide molecules to find candidates that bind with high affinity to different PADI4 conformations, using the RaPID system, performed in collaboration with Dr Walport and Prof Suga. First, the active calcium-soaked conformation of PADI4 was targeted to find active site inhibitors. Second, the active site was covalently blocked to identify possible activating peptides. Biochemical and cell biological assays revealed different peptides that bound tightly to both conformations of PADI4 (low nM binding affinity) and a biotinylated peptide was characterized for pulldown from lysates. Different peptides were shown both to inhibit and activate PADI4 with efficacy in vitro and in live cells. A toolkit of PADI4 specific cyclic peptide reagents can therefore be taken forward to address new biological questions. The activator in particular represents the first such cyclic peptide epigenetic activator. Finally, conditions for the cellular activation of PADI4 were used in highresolution proteomic analysis of PADI4 after affinity pulldown. Conditions were optimized to pulldown PADI4 using the new biotinylated cyclic peptide reagent developed in Chapter 5 and a commercial antibody. An irreversible inhibitor was used to distinguish allosteric interactors from substrates. Mass spectrometry showed that a number of proteins with established calciumbinding functions (EF-hand containing proteins), including calmodulin, were enriched for allosteric binding to the inactive conformation of PADI4. The interaction, which was enriched in the absence of calcium, was confirmed by reciprocal pulldown of calmodulin. In vitro experiments showed that recombinant calmodulin activates PADI4 at a reduced calcium concentration. Putative calmodulin binding sites were identified on PADI4 using bioinformatic analysis. These can be readily mutated by site-directed mutagenesis and PADI4 variants introduced into cells for future validation of the effect in cells. This work represents clear progress towards understanding a complete mechanism for PADI4 activation in cells.","abstract_html":"Five peptidylarginine deiminases (PADIs), regulating diverse aspects of human physiology, catalyse the post-translational modification citrullination in mammals. Deregulation of citrullination underlies the development of diverse pathologies and PADI4 is of particular medical interest in autoimmune diseases and in cancer. PADI activation is understood biochemically at the level of the crystal structure where allosteric calcium ion binding drives an extensive conformational change and the nucleophilic cysteine relocates approximately 5-10 Å. The critical open question for the field is how this activation can occur in cells. The calcium concentrations required to drive the conformational change in vitro are supraphysiological by two orders of magnitude and little is understood mechanistically about how cellular signalling events enable PADI enzyme activation. As such, the biological activation and therefore the deregulation of PADIs in diseases have remained enigmatic. This PhD set out to understand the physiological activation and regulation of the PADI4 enzyme. First, I identified a surprising origin of the mammalian PADI enzyme family as deriving from an ancient horizontal gene transfer event from cyanobacteria. A variety of maximum likelihood and Bayesian phylogenetic methods as well as non-parametric protein sequence analyses revealed that animal PADIs did not derive from the last universal common ancestor by conventional vertical descent and instead represent an ancient horizontal acquisition. The cyanobacterial PADI is shown to be active with a more stringent calcium dependency than the mammalian counterpart. This has particular interest as to how mechanisms for physiological activation of the human enzyme may have evolved and provides a rare example of HGT into the human lineage. Then, tractable conditions were established for comparing resting PADI4 to activated PADI4 across a variety of cell systems relevant to innate immunity and pluripotency. Emphasis was placed on identifying cellular stimuli that may be independent of calcium flux or transcriptional changes and in which the levels of PADI4 protein may be stringently controlled and independent from the activating stimulus. In this model system, PADI4 was shown to be activated by canonical Wnt signalling – downstream of recombinant Wnt3a, short-term GSK3β inhibition and chemical Wnt agonism. PADI4 inhibition reduced Wnt-driven transcription in a reporter assay. A role for PADI4 in Wnt signalling would be important for roles in haematopoetic stem cells, in neutrophils, in the establishment of pluripotency and its overexpression in cancer. Future work will be required to confirm these exciting effects in a physiologically relevant context. Next, work was undertaken to screen a vast library of peptide molecules to find candidates that bind with high affinity to different PADI4 conformations, using the RaPID system, performed in collaboration with Dr Walport and Prof Suga. First, the active calcium-soaked conformation of PADI4 was targeted to find active site inhibitors. Second, the active site was covalently blocked to identify possible activating peptides. Biochemical and cell biological assays revealed different peptides that bound tightly to both conformations of PADI4 (low nM binding affinity) and a biotinylated peptide was characterized for pulldown from lysates. Different peptides were shown both to inhibit and activate PADI4 with efficacy in vitro and in live cells. A toolkit of PADI4 specific cyclic peptide reagents can therefore be taken forward to address new biological questions. The activator in particular represents the first such cyclic peptide epigenetic activator. Finally, conditions for the cellular activation of PADI4 were used in highresolution proteomic analysis of PADI4 after affinity pulldown. Conditions were optimized to pulldown PADI4 using the new biotinylated cyclic peptide reagent developed in Chapter 5 and a commercial antibody. An irreversible inhibitor was used to distinguish allosteric interactors from substrates. Mass spectrometry showed that a number of proteins with established calciumbinding functions (EF-hand containing proteins), including calmodulin, were enriched for allosteric binding to the inactive conformation of PADI4. The interaction, which was enriched in the absence of calcium, was confirmed by reciprocal pulldown of calmodulin. In vitro experiments showed that recombinant calmodulin activates PADI4 at a reduced calcium concentration. Putative calmodulin binding sites were identified on PADI4 using bioinformatic analysis. These can be readily mutated by site-directed mutagenesis and PADI4 variants introduced into cells for future validation of the effect in cells. This work represents clear progress towards understanding a complete mechanism for PADI4 activation in cells.","abstract_has_math":false,"creators":["Cummings, Thomas Felix Martin"],"institution":"The University of Edinburgh","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Christophorou, Maria","Ponting, Chris","Acosta, Juan Carlos"],"committee_chairs":[],"committee_members":[],"year":2020,"date_issued":"2020-06-27","date_published":"2020-06-27","updated_at":"2026-11-19T03:35:01Z","subjects":["citrullination","PADI4","activation","PTM","horizontal gene transfer","HGT","cyclic peptide","peptidyl arginine deiminase","PADI","cyanobacteria","evolution","phylogenetics"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://dx.doi.org/10.7488/era/468"],"render_values":[{"text":"http://dx.doi.org/10.7488/era/468","href":"http://dx.doi.org/10.7488/era/468","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/1842/37167","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/1842/37167","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://era.ed.ac.uk/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aera.ed.ac.uk%3A1842%2F37167","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Christophorou, Maria","Ponting, Chris","Acosta, Juan Carlos"]},{"key":"dc:contributor.sponsor","label":"Sponsor","values":["Medical Research Council (MRC)"]},{"key":"dc:creator","label":"Author","values":["Cummings, Thomas Felix Martin"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2020-06-22T11:37:19Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2020-06-22T11:37:19Z"]},{"key":"dc:date.issued","label":"Date","values":["2020-06-27"]},{"key":"dc:publisher","label":"Institution","values":["The University of Edinburgh"]},{"key":"dc:type","label":"Dc Type","values":["Thesis or Dissertation"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["Doctoral"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["PhD Doctor of Philosophy"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["citrullination","PADI4","activation","PTM","horizontal gene transfer","HGT","cyclic peptide","peptidyl arginine deiminase","PADI","cyanobacteria","evolution","phylogenetics"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/1842/37167","http://dx.doi.org/10.7488/era/468"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Five peptidylarginine deiminases (PADIs), regulating diverse aspects of human physiology, catalyse the post-translational modification citrullination in mammals. Deregulation of citrullination underlies the development of diverse pathologies and PADI4 is of particular medical interest in autoimmune diseases and in cancer. PADI activation is understood biochemically at the level of the crystal structure where allosteric calcium ion binding drives an extensive conformational change and the nucleophilic cysteine relocates approximately 5-10 Å. The critical open question for the field is how this activation can occur in cells. The calcium concentrations required to drive the conformational change in vitro are supraphysiological by two orders of magnitude and little is understood mechanistically about how cellular signalling events enable PADI enzyme activation. As such, the biological activation and therefore the deregulation of PADIs in diseases have remained enigmatic. This PhD set out to understand the physiological activation and regulation of the PADI4 enzyme. First, I identified a surprising origin of the mammalian PADI enzyme family as deriving from an ancient horizontal gene transfer event from cyanobacteria. A variety of maximum likelihood and Bayesian phylogenetic methods as well as non-parametric protein sequence analyses revealed that animal PADIs did not derive from the last universal common ancestor by conventional vertical descent and instead represent an ancient horizontal acquisition. The cyanobacterial PADI is shown to be active with a more stringent calcium dependency than the mammalian counterpart. This has particular interest as to how mechanisms for physiological activation of the human enzyme may have evolved and provides a rare example of HGT into the human lineage. Then, tractable conditions were established for comparing resting PADI4 to activated PADI4 across a variety of cell systems relevant to innate immunity and pluripotency. Emphasis was placed on identifying cellular stimuli that may be independent of calcium flux or transcriptional changes and in which the levels of PADI4 protein may be stringently controlled and independent from the activating stimulus. In this model system, PADI4 was shown to be activated by canonical Wnt signalling – downstream of recombinant Wnt3a, short-term GSK3β inhibition and chemical Wnt agonism. PADI4 inhibition reduced Wnt-driven transcription in a reporter assay. A role for PADI4 in Wnt signalling would be important for roles in haematopoetic stem cells, in neutrophils, in the establishment of pluripotency and its overexpression in cancer. Future work will be required to confirm these exciting effects in a physiologically relevant context. Next, work was undertaken to screen a vast library of peptide molecules to find candidates that bind with high affinity to different PADI4 conformations, using the RaPID system, performed in collaboration with Dr Walport and Prof Suga. First, the active calcium-soaked conformation of PADI4 was targeted to find active site inhibitors. Second, the active site was covalently blocked to identify possible activating peptides. Biochemical and cell biological assays revealed different peptides that bound tightly to both conformations of PADI4 (low nM binding affinity) and a biotinylated peptide was characterized for pulldown from lysates. Different peptides were shown both to inhibit and activate PADI4 with efficacy in vitro and in live cells. A toolkit of PADI4 specific cyclic peptide reagents can therefore be taken forward to address new biological questions. The activator in particular represents the first such cyclic peptide epigenetic activator. Finally, conditions for the cellular activation of PADI4 were used in highresolution proteomic analysis of PADI4 after affinity pulldown. Conditions were optimized to pulldown PADI4 using the new biotinylated cyclic peptide reagent developed in Chapter 5 and a commercial antibody. An irreversible inhibitor was used to distinguish allosteric interactors from substrates. Mass spectrometry showed that a number of proteins with established calciumbinding functions (EF-hand containing proteins), including calmodulin, were enriched for allosteric binding to the inactive conformation of PADI4. The interaction, which was enriched in the absence of calcium, was confirmed by reciprocal pulldown of calmodulin. In vitro experiments showed that recombinant calmodulin activates PADI4 at a reduced calcium concentration. Putative calmodulin binding sites were identified on PADI4 using bioinformatic analysis. These can be readily mutated by site-directed mutagenesis and PADI4 variants introduced into cells for future validation of the effect in cells. This work represents clear progress towards understanding a complete mechanism for PADI4 activation in cells."]},{"key":"dc:title","label":"Title","values":["Evolutionary origin, cyclic peptide targeting and physiological activation of Peptidyl Arginine Deiminase 4"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Christophorou, Maria","Ponting, Chris","Acosta, Juan Carlos"],"dc:contributor.sponsor":["Medical Research Council (MRC)"],"dc:creator":["Cummings, Thomas Felix Martin"],"dc:date.accessioned":["2020-06-22T11:37:19Z"],"dc:date.available":["2020-06-22T11:37:19Z"],"dc:date.issued":["2020-06-27"],"dc:description.abstract":["Five peptidylarginine deiminases (PADIs), regulating diverse aspects of human physiology, catalyse the post-translational modification citrullination in mammals. Deregulation of citrullination underlies the development of diverse pathologies and PADI4 is of particular medical interest in autoimmune diseases and in cancer. PADI activation is understood biochemically at the level of the crystal structure where allosteric calcium ion binding drives an extensive conformational change and the nucleophilic cysteine relocates approximately 5-10 Å. The critical open question for the field is how this activation can occur in cells. The calcium concentrations required to drive the conformational change in vitro are supraphysiological by two orders of magnitude and little is understood mechanistically about how cellular signalling events enable PADI enzyme activation. As such, the biological activation and therefore the deregulation of PADIs in diseases have remained enigmatic. This PhD set out to understand the physiological activation and regulation of the PADI4 enzyme. First, I identified a surprising origin of the mammalian PADI enzyme family as deriving from an ancient horizontal gene transfer event from cyanobacteria. A variety of maximum likelihood and Bayesian phylogenetic methods as well as non-parametric protein sequence analyses revealed that animal PADIs did not derive from the last universal common ancestor by conventional vertical descent and instead represent an ancient horizontal acquisition. The cyanobacterial PADI is shown to be active with a more stringent calcium dependency than the mammalian counterpart. This has particular interest as to how mechanisms for physiological activation of the human enzyme may have evolved and provides a rare example of HGT into the human lineage. Then, tractable conditions were established for comparing resting PADI4 to activated PADI4 across a variety of cell systems relevant to innate immunity and pluripotency. Emphasis was placed on identifying cellular stimuli that may be independent of calcium flux or transcriptional changes and in which the levels of PADI4 protein may be stringently controlled and independent from the activating stimulus. In this model system, PADI4 was shown to be activated by canonical Wnt signalling – downstream of recombinant Wnt3a, short-term GSK3β inhibition and chemical Wnt agonism. PADI4 inhibition reduced Wnt-driven transcription in a reporter assay. A role for PADI4 in Wnt signalling would be important for roles in haematopoetic stem cells, in neutrophils, in the establishment of pluripotency and its overexpression in cancer. Future work will be required to confirm these exciting effects in a physiologically relevant context. Next, work was undertaken to screen a vast library of peptide molecules to find candidates that bind with high affinity to different PADI4 conformations, using the RaPID system, performed in collaboration with Dr Walport and Prof Suga. First, the active calcium-soaked conformation of PADI4 was targeted to find active site inhibitors. Second, the active site was covalently blocked to identify possible activating peptides. Biochemical and cell biological assays revealed different peptides that bound tightly to both conformations of PADI4 (low nM binding affinity) and a biotinylated peptide was characterized for pulldown from lysates. Different peptides were shown both to inhibit and activate PADI4 with efficacy in vitro and in live cells. A toolkit of PADI4 specific cyclic peptide reagents can therefore be taken forward to address new biological questions. The activator in particular represents the first such cyclic peptide epigenetic activator. Finally, conditions for the cellular activation of PADI4 were used in highresolution proteomic analysis of PADI4 after affinity pulldown. Conditions were optimized to pulldown PADI4 using the new biotinylated cyclic peptide reagent developed in Chapter 5 and a commercial antibody. An irreversible inhibitor was used to distinguish allosteric interactors from substrates. Mass spectrometry showed that a number of proteins with established calciumbinding functions (EF-hand containing proteins), including calmodulin, were enriched for allosteric binding to the inactive conformation of PADI4. The interaction, which was enriched in the absence of calcium, was confirmed by reciprocal pulldown of calmodulin. In vitro experiments showed that recombinant calmodulin activates PADI4 at a reduced calcium concentration. Putative calmodulin binding sites were identified on PADI4 using bioinformatic analysis. These can be readily mutated by site-directed mutagenesis and PADI4 variants introduced into cells for future validation of the effect in cells. This work represents clear progress towards understanding a complete mechanism for PADI4 activation in cells."],"dc:identifier.uri":["https://hdl.handle.net/1842/37167","http://dx.doi.org/10.7488/era/468"],"dc:language.iso":["en"],"dc:publisher":["The University of Edinburgh"],"dc:subject":["citrullination","PADI4","activation","PTM","horizontal gene transfer","HGT","cyclic peptide","peptidyl arginine deiminase","PADI","cyanobacteria","evolution","phylogenetics"],"dc:title":["Evolutionary origin, cyclic peptide targeting and physiological activation of Peptidyl Arginine Deiminase 4"],"dc:type":["Thesis or Dissertation"],"dc:type.qualificationlevel":["Doctoral"],"dc:type.qualificationname":["PhD Doctor of Philosophy"],"others:access_status":["open.access"]},"updated_at":"2026-11-19T03:35:01Z"}